LAUSR

The methacholine challenge test (MCT) is a diagnostic test required in many cases of suspected asthma.1,2 GEMA and GINA guidelines state that is more useful for ruling out asthma than for confirming it, but neither specify whether it should be performed with regular medication nor if this should have been suspended previously.1,2 This is relevant, as sensitivity to the test falls to 77% when the patients are using their regular treatment,3 as frequently occurs in patients referred to a specialized clinic. In these circumstances, the doctor should decide whether to maintain treatment or to suspend it before the MCT. The aim of this letter is to share our experience about the safety of suspending regular treatment before the MCT. To this aim, we reviewed the electronic medical records of 523 patients in whom MCT was requested between 2010 and 2016. Of these 88 (70% women, mean age: 50.4 years) were selected because they were receiving regular medication before the consultation (50% combined inhaled corticosteroid and long-acting -agonist, 13.6% inhaled corticosteroid in monotherapy, and 13.5% triple therapy) and interrupted, who suspended their medication until the MCT was conducted (with the exception of salbutamol, as needed). All patients were instructed to go urgently to the Respiratory Medicine Day Clinic in case of worsening. The most common symptom was cough (75%), followed by dyspnea (66%) and self-reported wheezing (42%), and in 18%, an exacerbation was recorded in their clinical records. Allergy skin tests were positive in 30.5% of cases, and median level of eosinophils in blood was 200 cells×106/l. None of the patients had FEV1/FVC <70%, and only 3% had a positive bronchodilator challenge. FENO values were higher than 50 ppb in 11.9%. In the period between suspension of medication and performance of the MCT (median 113 days, range: 23–445), 7 patients (8.4%) sought medical attention for clinical worsening. After medical and functional examination, signs of asthma were found in only 1 individual. In 2 additional cases (2.4%), asthma was diagnosed on the same day of the MCT due to significant decline in FEV1. None of the patients developed a severe exacerbation. Five patients (5.7%) were lost to follow-up, and by reviewing the electronic medical record, it was established that only 1 of them was treated for asthma in